Dr. Levine is a nationally-recognized expert in surgical oncology and the treatment of peritoneal mesothelioma.

About Dr. Levine

Dr. Levine is a board certified surgeon who is nationally recognized in the field of surgical oncology. He leads the mesothelioma surgical program at the number two hospital in the entire state of North Carolina. Although he is based out of Winston-Salem, Dr. Levine treats patients around the country.

  • Medical Degree and Residencies

    M.D., Finch University of Health Science/Chicago Medical School, 1985. Dr. Levine completed his residencies in surgery and oncology at the Michael Reese Medical Center and University of Illinois Hospital in the early 1990s.

  • Professorship

    Chief of surgical sciences, professor at Wake Forest University and director-at-large of Wake Forest Comprehensive Cancer Center.

Some of Dr. Levine’s patients travel to his hospital from out of state for his expertise in treating peritoneal mesothelioma. But for many others he works through oncologists and physicians in his patients’ home cities.

Dr. Levine treats patients with peritoneal mesothelioma. He is also a principal investigator of approximately 25 ongoing clinical research trials.

Dr. Levine is considered an internationally-renowned expert on the treatment of peritoneal mesothelioma with heated intraoperative chemotherapy (HIPEC) and cytoreductive surgery. This two-phase approach to treating peritoneal mesothelioma has done much to extend the lives of patients.

After completing his medical training and coming to Wake Forest, Dr. Levine worked at Louisiana State University before joining the staff at Wake Forest Baptist Medical Center in 1998.

Since then, Dr. Levine has served as a leader in the Wake Forest Comprehensive Cancer Center, where he is chief of the surgical oncology service. The Comprehensive Cancer Center has over 120 clinicians specializing in cancer care, and is the only National Cancer Institute-designated facility in western North Carolina. His other accolades include memberships in several prestigious surgical societies, and being listed in Best Doctors in America and Top Doctors for Cancer for over five consecutive years.

Dr. Levine’s Accomplishments

  • Selected for inclusion in Castle Connolly’s America’s Top Doctors every year since 2008
  • Selected for inclusion in Castle Connolly’s America’s Top Doctors for Cancer every year since 2005
  • CMS Meaningful Use Stage 1 Certification
  • EpicCare Inpatient — Core EMR, Epic Systems Corporation, 2012

Get Connected To Dr. Edward Levine

Photograph of Dr Levine
Dr. Levine is a renowned surgical oncologist and expert on peritoneal mesothelioma treatment. He has an impressive and long background on HIPEC and cytoreductive surgery, as a physician and a research specialist. He has also been awarded several prestigious accolades by his peers.

Why Choose Dr. Levine?
  • Over 30 years experience
  • Expert on HIPEC and cytoreductive surgery
  • Works with the oncologists of long-distance patients




Dr. Levine's Treatment and Research

Dr. Levine is the head of the cytoreductive surgery and HIPEC program at Wake Forest, where he also enjoys teaching and administrative duties.

In 2011, Dr. Levine was the principal investigator for 25 clinical/translational protocols. For this work, the National Cancer Alliance (NCA), various industries and the Comprehensive Cancer Center awarded him several grants for his research involving genomic analysis of solid tumors.

As of 2014, Wake Forest Baptist Medical Center, where Dr. Levine is affiliated, has the largest reported, single-center experience with cytoreductive surgery and HIPEC.

Heated Intraoperative Chemotherapy

In 2009, Dr. Levine led a team of physicians to study the data of over 400 mesothelioma patients who underwent cytoreduction with HIPEC. These patients had been diagnosed with diffuse malignant peritoneal mesothelioma (DMPM), an uncommon and locally aggressive type of mesothelioma with a typically poor prognosis.

According to the study, the median overall survival time was close to 53 months, with a five-year survival rate of 47%. This shows that meaningful long-term survival is possible for some patients with peritoneal mesothelioma when treated with cytoreductive surgery and HIPEC.

“The old axiom in medicine is if you hear hoofbeats, think horses,” Dr. Levine said. “Mesothelioma is not a horse; it’s not even a zebra. This is more like a yak. It is a rare tumor, and it amazes me that we’ve been able to learn as much about it as we have, for a disease as rare as it is.”

Want to get connected with Dr. Levine? Try our free Doctor Match program.